Surrogate end points in oncology: aligning drug development incentives and patient needs

Matthew Vogel, Rona Yaeger, David J. Stewart, Vivek Subbiah, Frank S. David

Open source

DOI
10.1038/s41571-025-01031-z
Published
2025-06-06
Container
Nature Reviews Clinical Oncology
Publisher
Springer Science and Business Media LLC
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1038/s41571-025-01031-z,
  title = {Surrogate end points in oncology: aligning drug development incentives and patient needs},
  author = {Matthew Vogel and Rona Yaeger and David J. Stewart and Vivek Subbiah and Frank S. David},
  year = {2025},
  journal = {Nature Reviews Clinical Oncology},
  doi = {10.1038/s41571-025-01031-z},
  url = {https://doi.org/10.1038/s41571-025-01031-z}
}

RIS

TY  - JOUR
TI  - Surrogate end points in oncology: aligning drug development incentives and patient needs
AU  - Matthew Vogel
AU  - Rona Yaeger
AU  - David J. Stewart
AU  - Vivek Subbiah
AU  - Frank S. David
PY  - 2025
JO  - Nature Reviews Clinical Oncology
DO  - 10.1038/s41571-025-01031-z
UR  - https://doi.org/10.1038/s41571-025-01031-z
ER  - 

APA

Vogel, M., Yaeger, R., Stewart, D. J., Subbiah, V., & David, F. S. (2025). Surrogate end points in oncology: aligning drug development incentives and patient needs. Nature Reviews Clinical Oncology. https://doi.org/10.1038/s41571-025-01031-z

Source records